ATE383345T1 - Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. - Google Patents

Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.

Info

Publication number
ATE383345T1
ATE383345T1 AT04729421T AT04729421T ATE383345T1 AT E383345 T1 ATE383345 T1 AT E383345T1 AT 04729421 T AT04729421 T AT 04729421T AT 04729421 T AT04729421 T AT 04729421T AT E383345 T1 ATE383345 T1 AT E383345T1
Authority
AT
Austria
Prior art keywords
compounds
receptor antagonists
orexin receptor
quinoxalin
preparation
Prior art date
Application number
AT04729421T
Other languages
English (en)
Inventor
Hamed Aissaoui
Martine Clozel
Thomas Weller
Ralf Koberstein
Thierry Sifferlen
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE383345T1 publication Critical patent/ATE383345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
AT04729421T 2003-04-28 2004-04-26 Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. ATE383345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0304491 2003-04-28

Publications (1)

Publication Number Publication Date
ATE383345T1 true ATE383345T1 (de) 2008-01-15

Family

ID=33395689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04729421T ATE383345T1 (de) 2003-04-28 2004-04-26 Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.

Country Status (8)

Country Link
US (1) US7538109B2 (de)
JP (1) JP2007523846A (de)
CN (1) CN1780820A (de)
AT (1) ATE383345T1 (de)
CA (1) CA2520839A1 (de)
DE (1) DE602004011204T2 (de)
ES (1) ES2297413T3 (de)
WO (1) WO2004096780A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007245037A1 (en) * 2006-03-29 2007-11-08 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
US8618102B2 (en) 2006-07-14 2013-12-31 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) * 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
CN101627007A (zh) * 2007-03-05 2010-01-13 弗·哈夫曼-拉罗切有限公司 用作食欲肽拮抗剂的氨基酰胺
CA2679985A1 (en) * 2007-03-15 2008-09-18 F. Hoffmann-La Roche Ag Malonamides as orexin antagonists
US8242121B2 (en) 2007-05-23 2012-08-14 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
JP2010528007A (ja) 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
KR101204213B1 (ko) * 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
WO2009128262A1 (ja) * 2008-04-15 2009-10-22 武田薬品工業株式会社 キノロン誘導体およびその用途
PL2491038T3 (pl) 2009-10-23 2016-10-31 Dwupodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
KR20140124398A (ko) 2012-02-07 2014-10-24 이올라스 테라퓨틱스, 인코포레이티드 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
RS63471B1 (sr) 2016-02-12 2022-08-31 Astrazeneca Ab Halo-supstituisani piperidini kao modulatori receptora oreksina
HUE058759T2 (hu) 2016-03-10 2022-09-28 Janssen Pharmaceutica Nv Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
EP1075478B1 (de) 1998-05-08 2003-04-16 SmithKline Beecham plc Phenylurea und phenylthio urea derivate
WO2000047580A2 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives
ES2226785T3 (es) * 1999-02-12 2005-04-01 Smithkline Beecham Plc Derivados de fenilurea como antagonistas de los receptores de orexina.
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
DE60108236T2 (de) 2000-03-14 2005-12-22 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
EP1353918B1 (de) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
CN100448874C (zh) 2001-05-05 2009-01-07 史密斯克莱·比奇曼公司 N-芳酰基环胺
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
EP1705179A1 (de) 2001-06-28 2006-09-27 Smithkline Beecham Plc N-Aroyl Zyklische Aminderivate als Orexin Rezeptor Antagonisten
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
NZ538029A (en) 2002-07-09 2006-08-31 Actelion Pharmaceuticals Ltd 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives

Also Published As

Publication number Publication date
CN1780820A (zh) 2006-05-31
ES2297413T3 (es) 2008-05-01
WO2004096780A1 (en) 2004-11-11
US7538109B2 (en) 2009-05-26
US20070027157A1 (en) 2007-02-01
DE602004011204D1 (de) 2008-02-21
CA2520839A1 (en) 2004-11-11
DE602004011204T2 (de) 2008-12-24
JP2007523846A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
IL155806A0 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
ATE433447T1 (de) Pyrimiidinverbindungen
MXPA03004780A (es) Nuevas sulfamidas.
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
ECSP045378A (es) Derivados novedosos de diazabiciclononeno
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
ATE274515T1 (de) Pyrazolopyridinderivate
TW200621774A (en) Bicyclononene derivatives
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel
NO20022971L (no) Butyndiol-derivater
MXPA05014081A (es) Derivados de benzofurano y su uso en el tratamiento de infecciones microbianas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties